# Hemab Therapeutics Holdings, Inc.: overview COAG · Nasdaq · CIK 2114044 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/coag.md) · [Financials](/companies/coag/financials.md) · [Filings](/companies/coag/filings.md) · [Insiders](/companies/coag/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(16.18)](/filings/0001193125-26-234386.md) | [(12.91)](/filings/0001193125-26-344533.md) | [(23.98)](/filings/0001193125-26-234386.md) | [(0.80)](/filings/0001193125-26-344533.md) | | Free cash flow | $m | [(13.0)](/filings/0001193125-26-234386.md) | [(15.3) d](/filings/0001193125-26-344533.md) | [(21.7)](/filings/0001193125-26-234386.md) | [(22.7) d](/filings/0001193125-26-344533.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure. ## Last five fiscal years Not reported. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/coag/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $286.8m | 7,808,627 | | New +7,808,627 | | [NOVO HOLDINGS A/S](/funds/1388325.md) | 2026-06-30 | $153.6m | 4,180,550 | | New +4,180,550 | | [FMR LLC](/funds/315066.md) | 2026-06-30 | $135.8m | 3,697,837 | | New +3,697,837 | | [Capital International Investors](/funds/1562230.md) | 2026-06-30 | $132.4m | 3,603,876 | | New +3,603,876 | | [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $132.3m | 3,602,093 | | New +3,602,093 | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $76.6m | 2,086,834 | | New +2,086,834 | | [Avoro Capital Advisors LLC](/funds/1633313.md) | 2026-06-30 | $70.7m | 1,925,150 | | New +1,925,150 | | [Bain Capital Life Sciences Investors, LLC](/funds/1703031.md) | 2026-06-30 | $60.6m | 1,650,000 | | New +1,650,000 | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $42.3m | 1,152,420 | | New +1,152,420 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $28.7m | 780,758 | | New +780,758 | ## Recent filings [All 50 filings](/companies/coag/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-24 | 16:03 ET | [8-K](/filings/0001193125-26-401010.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-401010 | | 2026-08-11 | 16:00 ET | [10-Q](/filings/0001193125-26-344533.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344533 | | 2026-08-11 | 07:11 ET | [8-K](/filings/0001193125-26-343421.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-343421 | | 2026-05-21 | 16:02 ET | [10-Q](/filings/0001193125-26-234386.md) | Quarterly report, period 2026-03-31 | 0001193125-26-234386 | | 2026-05-21 | 07:05 ET | [8-K](/filings/0001193125-26-233375.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-233375 | | 2026-05-11 | 16:43 ET | [SCHEDULE 13D](/filings/0001193125-26-216973.md) | Ownership report, active investor | 0001193125-26-216973 | | 2026-05-11 | 16:01 ET | [8-K](/filings/0001193125-26-216699.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-216699 | | 2026-05-04 | 16:09 ET | [8-K](/filings/0001193125-26-203988.md) | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-203988 | | 2026-04-30 | 06:39 ET | [S-1/A](/filings/0001193125-26-193885.md) | Registration statement, amended | 0001193125-26-193885 | | 2026-04-28 | 16:08 ET | [S-1/A](/filings/0001193125-26-186964.md) | Registration statement, amended | 0001193125-26-186964 | ## Latest annual report No annual report is in coverage. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 2114044 - Tickers: COAG - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.